As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income ...

Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE at its earnings and acquisition.

Pfizer (PFE) stock is in focus as a mid-stage trial for the company's investigational breast cancer therapy, atirmociclib succeeds. Read more here.

Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE.

Qure shares finished the regular trading week down only 9% despite the FDA’s hard-line stance and public criticism against the company’s Huntington’s disease (HD) gene therapy candidate AMT-130.

The stock is down, but the good news is that it sports a fat dividend yield of 6.4%. Pfizer has been struggling lately, but it has a rich pipeline of drugs in development. The pharmaceutical giant ...

If you ask me for a reason I'd buy Pfizer (NYSE: PFE) stock and never sell it, I certainly have one -- because I've already bought into Pfizer, and I have no plans to sell it. Here's a look at why I ...

Kalshi prediction contracts put the odds of an S&P 500 correction around 58% in 2026. The stock market tends to suffer a steep decline during midterm election years. Contracts on the popular ...

Individual investors who embraced high-risk, high-reward stock bets in recent years are now flocking to prediction markets. For the cohort that piled into options—which give the right to buy or sell a ...

DraftKings missed the mark with its guidance for this year as it plans steep investments in prediction markets. The lines between sports betting and prediction markets are already blurry, but ...